As the global pharmaceutical industry enters a period of profound transition, this episode of Corner Office Conversation examines what lies ahead. Hosts Vikas Dandekar and Teena Thacker talk to Stefan Oelrich, Head of the Pharmaceuticals Division at Bayer AG, about the forces reshaping drug discovery and access from trade tensions and shifting innovation hubs to the promise and uncertainty of cell and gene therapies. Oelrich reflects on Europe’s struggle to stay competitive as capital and talent flow increasingly toward the US and China, and argues that meaningful reform will require faster regulation, leaner bureaucracy, and quicker patient access. He also addresses the looming loss of exclusivity for blockbuster drugs and outlines how Bayer plans to offset revenue impact with a packed pipeline of new launches. India emerges as both an opportunity and a test case, offering scale and growth while raising tough questions on affordability and access. At its core, the conversation asks whether breakthrough science can move fast enough to serve patients without losing public trust.
You can follow Vikas Dandekar on his social media: X and Linkedin and read his Newspaper Articles.
You can follow Teena Thacker on his social media: X and Linkedin and read her Newspaper Articles.
Listen to Corner Office Conversation: Corner Office Conversation with Knight Frank’s William Beardmore-Gray and Shishir Baijal, Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with Elizabeth Reid, Head of Search, Google and much more.
Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.
See omnystudio.com/listener for privacy information.
